Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : China Warehouse- More Than Crockery -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (3340)	7/12/2004 1:37:00 PM
From: RealMuLan	Read Replies (1) \| Respond to of 6370

China's first Therapeutic Vaccine of Hepatitis B into clinic trial www.chinaview.cn 2004-07-12 17:00:31 BEIJING, July 12 (Xinhuanet) -- China's first therapeutic Hepatitis B vaccine, which will make possible for Hepatitis B carriers and patients to be cured, has been approved for a second phase of clinical trials. 　So far 261 patients have successfully overcome the disease with the help of the therapeutic vaccine. CRIENGLISH.com reported Monday. 70 percent of patients in the immune clearance phase, which usually occurs later in life, can be cured if vaccinated on time. However, patients in the immune tolerant phase, which usually takes place at a young age, still show some resistance to the new treatment. The therapeutic Hepatitis B vaccine is an albumen vaccine. Two other potential vaccines, including DNA and polypeptide types are also being developed and are expected to be ready for use in five to six years. (CRIENGLISH.com) news.xinhuanet.com